AIM: This analysis aimed to assess the annual International Unit (IU) consumption and costs of prophylaxis therapies with extended half-life recombinant FVIII (EHL-rFVIII), targeting a traditional trough level of 1% and the higher levels of 3% and 5% recommended by recent guidelines and expert...
